Stay updated with breaking news from Director Gordon. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Humacyte, Inc. (NASDAQ:HUMA – Get Free Report) hit a new 52-week high on Wednesday . The stock traded as high as $7.80 and last traded at $7.76, with a volume of 573253 shares. The stock had previously closed at $7.49. Analyst Upgrades and Downgrades HUMA has been the topic of several recent research reports. Cantor […]
Humacyte, Inc. (NASDAQ:HUMA – Get Free Report) shot up 4.9% during trading on Tuesday . The company traded as high as $7.50 and last traded at $7.50. 165,917 shares changed hands during mid-day trading, a decline of 88% from the average session volume of 1,347,385 shares. The stock had previously closed at $7.15. Analyst Upgrades […]
Shares of Humacyte, Inc. (NASDAQ:HUMA – Get Free Report) saw strong trading volume on Wednesday after an insider bought additional shares in the company. 891,494 shares traded hands during trading, a decline of 25% from the previous session’s volume of 1,189,422 shares.The stock last traded at $6.65 and had previously closed at $6.42. Specifically, Director […]
Humacyte, Inc. (NASDAQ:HUMA – Get Free Report) Director Gordon M. Binder purchased 50,000 shares of the firm’s stock in a transaction that occurred on Wednesday, May 15th. The shares were bought at an average cost of $6.78 per share, for a total transaction of $339,000.00. Following the completion of the acquisition, the director now directly […]
Humacyte, Inc. (NASDAQ:HUMA – Get Free Report) Director Gordon M. Binder acquired 50,000 shares of the company’s stock in a transaction dated Wednesday, May 15th. The stock was acquired at an average cost of $6.78 per share, with a total value of $339,000.00. Following the transaction, the director now directly owns 160,000 shares of the […]